Home › Research › Mild cognitive impairment
Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217
Groot C, Cicognola C, Bali D, Triana-Baltzer G, Dage JL, Pontecorvo MJ, Kolb HC, Ossenkoppele R et al.. Alzheimer's research & therapy, 2022-05-14
Topic: Amyloid, tau and blood-test diagnosis
Background Recent advances in disease-modifying treatments highlight the need for accurately identifying individuals in early Alzheimer's disease (AD) stages and for monitoring of treatment effects. Plasma measurements of phosphorylated tau (p-tau) are a promising biomarker for AD, but different assays show varying diagnostic and prognostic accuracies. The objective of this study was to determine the clinical performance of a novel plasma p-tau217 (p-tau217) assay, p-tau217+ Janssen , and perform a head-to-head comparison to an established assay, plasma p-tau217 Lilly , within two independent cohorts . METHODS: The study consisted of two cohorts, cohort 1 (27 controls and 25 individuals with mild-cognitive impairment [MCI]) and cohort 2 including 147 individuals with MCI at baseline who were followed for an average of 4.92 (SD 2.09) years. Receiver operating characteristic analyses were used to assess the performance of both assays to detect amyloid-β status (+/-) in CSF, distinguish MCI from controls, and identify subjects who will convert from MCI to AD dementia. General linear and linear mixed-effects analyses were used to assess the associations between p-tau and baseline, and annual change in Mini-Mental State Examination (MMSE) scores. Spearman correlations were used to assess the associations between the two plasma measures, and Bland-Altmann plots were examined to assess the agreement between the assays. Results Both assays showed similar performance in detecting amyloid-β status in CSF (plasma p-tau217+ Janssen AUC = 0.91 vs plasma p-tau217 Lilly AUC = 0.89), distinguishing MCI from controls (plasma p-tau217+ Janssen AUC = 0.91 vs plasma p-tau217 Lilly AUC = 0.91), and predicting future conversion from MCI to AD dementia (plasma p-tau217+ Janssen AUC = 0.88 vs p-tau217 Lilly AUC = 0.89). Both assays were similarly related to baseline (plasma p-tau217+ Janssen rho = -0.39 vs p-tau217 Lilly rho = -0.35), and annual change in MMSE scores (plasma p-tau217+ Janssen r = -0.45 vs p-tau217 Lilly r = -0.41). Correlations between the two plasma measures were rho = 0.69, p Janssen and plasma p-tau217 Lilly in both cohorts (cohort 1, 51/52 [98%] within 95%CI; cohort 2, 139/147 [95%] within 95%CI). Conclusions Taken together, our results indicate good diagnostic and prognostic performance of the plasma p-tau217+ Janssen assay, similar to the p-tau217 Lilly assay.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Groot, C., Cicognola, C., Bali, D., Triana-Baltzer, G., Dage, J. L., Pontecorvo, M. J., et al. (2022). Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-022-01005-8
Vancouver
Groot C, Cicognola C, Bali D, Triana-Baltzer G, Dage JL, Pontecorvo MJ, et al. Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217. Alzheimer's research & therapy. 2022. doi:10.1186/s13195-022-01005-8. PMID: 35568889.
BibTeX
@article{groot2022-35568889,
author = {Groot, C. and Cicognola, C. and Bali, D. and Triana-Baltzer, G. and Dage, J. L. and Pontecorvo, M. J. and Kolb, H. C. and Ossenkoppele, R. and others},
title = {{Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217}},
journal = {Alzheimer's research \& therapy},
year = {2022},
doi = {10.1186/s13195-022-01005-8},
pmid = {35568889},
url = {https://doi.org/10.1186/s13195-022-01005-8}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Both assays showed similar performance in detecting amyloid-β status in CSF (plasma p-tau217+ Janssen AUC = 0.91 vs plasma p-tau217 Lilly AUC = 0.89), distinguishing MCI from controls (plasma p-tau217+ Janssen AUC = 0.91 vs plasma p-tau217 Lilly AUC = 0.91), and predicting future conversion from MCI to AD dementia (plasma p-tau217+ Janssen AUC = 0.88 vs p-tau217 Lilly AUC = 0.89).
- Conclusions Taken together, our results indicate good diagnostic and prognostic performance of the plasma p-tau217+ Janssen assay, similar to the p-tau217 Lilly assay.
Why it matters
This study found that a new plasma p-tau217 assay performed similarly to an established assay in detecting amyloid-β status, distinguishing mild cognitive impairment from controls, and predicting conversion to Alzheimer's dementia. It is a diagnostic and prognostic biomarker study and does not test any treatment, cure or prevention.
Study details
- Participants25
- Effect sizeAUC = 0.91; AUC = 0.89; AUC = 0.88
- Evidence strengthModerate
How this study scored 59/100
Published in a peer-reviewed journal. Scored zero for study design and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer's research & therapy) |
| Journal's citation record | 1 / 4 | Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 25 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 99 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 16.5 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 4 / 6 | Cited 11.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 16 other studies in this library |
| Still being cited | 3 / 4 | Cited 85 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Oskar Hansson: h-index 148 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Lund University: institution h-index 1,119 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35568889) |
| Free to read | 2 / 2 | Free to read |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13195-022-01005-8
- PubMed: 35568889
- Original source →
- Free full text: Alzheimer s Research & Therapy →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.
Later studies that cite this one
16 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Mild cognitive impairment
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.